Surgical treatment of the neck in patients with salivary gland carcinoma.

Autor: Westergaard-Nielsen M; Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark., Godballe C; Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark., Grau Eriksen J; Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark., Larsen SR; Department of Pathology, Odense University Hospital, Odense, Denmark., Kiss K; Department of Pathology, Rigshospitalet, Copenhagen, Denmark., Agander T; Department of Pathology, Rigshospitalet, Copenhagen, Denmark., Parm Ulhøi B; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., Wittenborg Charabi B; Department of Otorhinolaryngology, Head and Neck Surgery, Rigshospitalet, Copenhagen, Denmark., Ehlers Klug T; Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital, Aarhus, Denmark., Jacobsen H; Department of Otorhinolaryngology, Head and Neck Surgery, Aalborg University Hospital, Aalborg, Denmark., Johansen J; Department of Oncology, Odense University Hospital, Odense, Denmark., Kristensen CA; Department of Oncology, Rigshospitalet, Copenhagen, Denmark., Andersen E; Department of Oncology, Herlev, Denmark., Andersen M; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark., Bjørndal K; Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2021 Jun; Vol. 43 (6), pp. 1898-1911. Date of Electronic Publication: 2021 Mar 18.
DOI: 10.1002/hed.26667
Abstrakt: Background: Elective neck dissection (END) in patients with salivary gland carcinoma is controversial and there are no universally accepted guidelines.
Methods: Patients were identified from the Danish Head and Neck Cancer Group. Between 2006 and 2015, 259 patients with primary salivary gland carcinoma were treated with END. Variables potentially associated with regional metastases were analyzed using logistic regression. Neck recurrence-free survival was calculated using the Kaplan-Meier method.
Results: Occult metastases were found in 36 of the patients treated with END (14%) and were particularly frequent among patients with T3/T4 tumors and high-grade histology tumors. In multivariate analyses, high-grade histology and vascular invasion were associated with occult metastases.
Conclusion: We recommend END of levels II and III for patients with high-grade or unknown histological grade tumors, and for T3/T4 tumors. Levels I, II, and III should be included in END in patients with submandibular, sublingual, or minor salivary gland carcinomas.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: